HERV-K is a 50-copy, human endogenous, class 1 retroviral element that contains some polycistrons with gag, pol, and env open reading frames. Although expression of HERV-K proviruses has been shown in cultured human cell lines, expression of these elements has not been shown in human blood leukocytes. Using both reverse transcriptase-polymerase chain reaction and ribonuclease protection techniques, w e show HERV-K pol gene expression in human HE HUMAN GENOME contains many copies of en-
T dogenous retroviral (HERV) elements.' However, most are defective in the sense that they are truncated or carry mutations that preclude their coding for enzymatically active proteins. The L1* family of genes is the most abundant HERV-like element, containing approximately 10, OOO copies per genome. The consensus L1 sequence contains two open reading frames. The second, pol, encodes a reverse transcriptase (RT)-like polypeptide. Until recently, all sequenced L 1 elements contained defective RT-like genes. However, Dombroski et a13 identified the L1-1 subfamily comprised of six members, at least three of which code for a complete RT open reading frame. The RT-like protein expressed from one L1-1 element displayed the ability to reverse transcribe homopolymer RNA templates4; however, it is not known whether the potentially active LI-1 gene subfamily is expressed.
Ll elements are not typical retroviral elements in that they have only two open reading frames. They are conspicuously missing both an env gene and long terminal repeats (LTR). In typical class 1 retroviral elements, the LTR region normally contains transcription regulatory sequence^^.^ upstream of a primer binding site that combines with a tRNA primer. Formation of the RT-primer-template complex is required to initiate reverse transcription of retroviral genomes. ' The human genome contains several hundred copies of class 1 HERV,' which also appear to be defective. However, the 50-copy HERV-K family5 is unusual in that it contains several copies with pol genes that code for RT open reading frames. Ono et al' sequenced four members and found open gag, pol, and env reading frames as well as apparently intact LTR regions. The predicted genomic RNA of HERV-K contained a primer binding site capable of combining with human lysyl tRNA.5 Expression of 9-kb genomic HERV-K RNA transcripts was detected in a human breast cancer cell line stimulated with dexamethasone. 6 Shih et a19 used the RT-polymerase chain reaction (RT-PCR) employing degenerate PCR ' to demonstrate the expression of pol-like genes in human cell lines. They' showed expression in human cell lines of pol-like sequences that were related but not identical to pol transcripts of known retroviruses or endogenous retroviral elements.
Following the strategy mentioned above, we used PCR primers defining the sequences coding for the conserved LPQ-YIDD domain of the HERV-K pol gene to amplify nucleotide sequences coding for HERV-K RT reverse transcribed from human blood leukocyte RNA. We report here that freshly isolated blood leukocytes from normal individuals expressed a variety of HERV-K pol sequences. None were identical with the published HERV-K proviral sequence.' In contrast to this heterogeneous pattern of expression in normals, blood leukocytes from three patients with chronic myelogenous leukemia (CML) and two patients with acute myelogenous leukemia in remission (AML) expressed a common, defective HERV-K LPQ-YIDD pol sequence. Preliminary results suggested that the high relative abundance of one particular HERV-K transcript in leukemic cells resulted from selective regulation, rather than from extensive gene amplification.
MATERIALS AND METHODS

Patient characteristics.
The experimental group consisted of three patients with polycythemia vera (PV nos. 1 through 3); three with chronic myelogenous leukemia (CML nos. 1 through 3), and two with acute myelogenous leukemia (AML nos. 1 and 2). Only two cases showed blast cells in the peripheral blood, CML2 (86% blasts) and AML2 (5% blasts). PVl (CCo) was a 57-year-old black woman diagnosed in June 1980. PV2 (RKe) was a 71-year-old white man diagnosed in April 199 1. PV3 (CCa) was a 7 1-year-old white woman diagnosed in August 1984. CMLl (JCB) was a 32-year-old white man diagnosed in August 1988 and was in the first chronic phase of CML. CML2 (WCo) was a 44-year-old white man diagnosed as chronic phase CML in June 1989 and studied after a myeloid blastic transformation in May 1990. CML3 (RSe) was a 58-year-old white man diagnosed in December 1991 in the first chronic phase ofCML.
AMLl (APo) was a 47-year-old white woman diagnosed as AML (M-1) in September 1990, who was in hematologic remission at the time of the study. AML2 (WId) was a 61-year-old white man diagnosed as AML (M-7) in July 1992, the time of the study.
Heparinized blood ( 18 mL) was centrifuged at 1,000g. The bufy coat was suspended in 50 mL of freshly prepared RCLB, red blood cell (RBC) lysis buffer (4.15 g NH&1,0.5 g KHC03, and 100 pL of 0.5 mol/L EDTA, pH 7 brought to 500 mL with H20), and incubated for 10 minutes at room temperature to lyse erythrocytes. Leukocytes were pelleted by centrifugation, washed with phosphate-buffered saline, and counted in a hemocytometer. The supernatant was aspirated and the cell pellet was 
vortexted and dissolved at 10' cells/mL in GTSM (4 mol/L GuSCN, 0.1 mol/L Tris-HCI. pH 7.4, 0.5 mol/L sodium laurel sarcosinate, and 0.14 mol/L 2-mercaptoethanol). Duplicate aliquots of 150 pL were stored for RNase protection; the remainder of the lysate was diluted to 5 mL with GTSM for RNA extraction.
RNA puri/rcution. Total RNA was isolated by a modification of the acid guanidine-phenol-chloroform method." For every 5 mL of diluted lysate, 1.0 mL 3 mol/L NaOAC, pH 4.3, 5 mL phenol saturated with water and I mL of a 24:l mixture of CHC13:isoamyl alcohol were sequentially added and mixed in. The emulsion was incubated for 10 minutes on ice. Samples were then centrifuged at 1,500g for 15 minutes and the aqueous layer was removed and extracted once with CHC13. RNA in the aqueous layer was precipitated from I vol of isopropanol, rinsed with 100% ethanol, then with 90% EtOH, dried, and dissolved in RNase-free DNase solution (0.1 mol/ L NaCI. 0.01 mol/L MgC12, 0.01 mol/L Tris, pH 7.2 and 20 pg/mL of RNase-free DNase) and incubated 30 minutes at 37°C. RNA was reextracted with CHC13 and precipitated from alcohol. RNA was taken through a second cycle of digestion with DNase, extraction, and precipitation. PCR/rom RNA. PCR was performed on leukocyte RNA, using a modification of the procedure of Singer-Sam et ai." RNA was reverse transcribed with the HERV-K YIDD primer and PCR was conducted with HERV-K LPQ and YlDD primers. The upstream LPQ primer was 5'-ttcggatccTGGAAAGTGTTACCCAGG and the at 42°C for 15 minutes and 99°C for 5 minutes the reaction volume was adjusted to 75 pL by adding 6 pL of 25 mmol/L MgClz (final concentration = 2 mmol/L). 5.5 pL of IOX PCR buffer 11, 2.5 U Amplitaq DNA polymerase (Cetus), 2 pL of LPQ (Genosys) primer (final concentration = 0.5 pmol/L). cDNA was amplified by 30 cycles ofthree-temperature PCRwith Taq polymerase, using94"C I-minute denaturation. 60°C 2 minutes for primer annealing. and 72°C 2.5 minutes for polymerization. The final amplification included a polymerization stepat 72°C for 10 minutes. Amplification products were visualized by ethidium bromide staining after electrophoresis in 8% polyacrylamide.
PCR products were fractionated by electphoresis in 2.0% agarose, purified with glass powder." cleaved with BamHl and Hind111 endonuclease, and cloned into pGEM4Z. DNA sequencing was done according to Sanger et RTcoding. RNA transcripts in blood leukocytes were studies by lysate RNase protection'6 using a kit from DNA sequencing.
Ribonlickme protection.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From RNA Lab (Eagle. PA). Briefly, 5 pL containing IO6 cpm of HERV-K pol RNA probe ( IO9 cpm/pg) was added to 20 pL of cell lysates in GTSM. Hybrids formed at 37°C for I7 hours were blunt-ended by incubation with RNase A at 37°C for 60 minutes. RNase was inactivated with 100 pg/mL of protease K for 30 minutes at 37°C and nucleic acids were precipitated from a freshly prepared 99% ethanol: 1% DEPC solution. RNA-RNA hybrids were collected by centrifugation and analyzed by electrophoresis in 8% polyacrylamide.
DNA was purified from cell lysates with glass powder" and cleaved with EroRI. DNA ( 5 pg) was fractionated by electrophoresis through an 0.8% agarose gel, transferred to nitrocellulose, prehybridized for 4 hours with Denhardt's solution lacking bovine serum albumin (BSA), and hybridized with IO7 cpm/mL of 32P RNA probe for I7 hours at 65°C. Aner hybridization. the membrane was rinsed twice with 2X SSC, incubated for 60 minutes at 65°C in hybridization solution. rinsed twice with 2X SSC (0.3 mol/ L NaCI. 0.03 mol/L sodium citrate. pH 7.0). incubated for 30 minutes at 37°C in 0.4 mol/L NaCl containing 20 pg/mL of RNase A, rinsed twice in 2X SSC. and autoradiographed for 24 hours with x-ray film. 
RESULTS
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To verify that amplified sequences were derived from HERV-K RNA, the 148-bp amplification products were purified from agarose after electrophoresis, cloned, and sequenced. At least one clone from each amplification reaction containing an insert of the expected size was sequenced. PCR products cloned and sequenced from seven normal donors comprised five different sequences. Four were open reading frames closely related to HERV-K, containing the expected orientation of PCR primers and retroviral sequences (Fig 3) . One sequence, encountered in three normal donors (nos. 4, 6, and 7) contained a stop codon at nucleotide 41 (Fig 3) . Normal donor 4 also expressed another HERV-K sequence.
Four different sequences were obtained among 5 RNA preparations from PV patients. Two of the five PV sequences were not represented in the sequences from normal donors. Two of the 3 PV patients yielded sequences with nonconsensus nucleotides at positions 39, 42, and 45 (C..A..T), as did 1 of the 7 normals. One of the PV patients gave a sequence that was missing the position 39,42, and 45 nonconsensus nucleotides and was identical to the NOR2 sequence. Three sequences amplified from different RNA preparations of the same PV patient (CCo) were different.
RT sequences were also amplified from 5 leukemia patients, 2 with AML and 3 with CML. Of the CML patients, I was in blastic transformation and 2 had chronic phase disease. All 5 leukemia patients expressed a common sequence, the sequence with the stop codon encountered in 3 normal donors. One leukemia patient (AML2) expressed two different sequences (Fig 3) .
Two 133-bp amplification products were also cloned, one from a CML patient and one from a normal control. Both contained in-frame deletions that removed I5 nucleotides coding for TFVGR.
Lysate RNase protection experimentsI6 were performed to show directly that HERV-K sequences were expressed in blood cell RNA. Figure 4A shows that a full-length probetarget duplex was obtained after hybridization of RNA in lysates with the NOR I probe (top arrow). No signal was detected with a lysate that was diluted IO-fold (not shown). Shorter duplexes were also observed, possibly reflecting hybridization with other HERV-K RNA species. As expected from the sequences of Fig 3, fragments down to 30 bp were obtained in the presence of target but not in its absence (not shown). All of the lysates gave faint signals with an myc RNA probe, except for phytohemagglutinin (PHA)-stimulated blood cells, which gave a strong signal. The similar signals obtained with the GAPDH RNA probe showed that each of the lysates contained the same quantity of RNA. These results confirm that HERV-K sequences are expressed in fresh, un- A possible explanation for the relatively high abundance of one particular HERV-K pol sequence in leukemia blood cell RNA is an increase in DNA copy number of that particular HERV-K provirus. To test this, DNA was isolated from seven leukemia patients and seven normal controls and analyzed by Southern transfer. All 15 samples yielded approximately the same signal (Fig 5) . Quantitation by peak height densitometry showed that the hybridization signal from control DNA was slightly higher than from leukemia DNA, 106 f 21 mm versus 67 f 20 mm, but the difference was not statistically significant. If HERV-K proviruses were expressed randomly in blood cells of normal donors, there would have to be a several-fold increase in HERV-K genes, accounted for by amplification of the HERV-K provirus selectively expressed in leukemia. No evidence for HERV-K gene amplification was obtained.
DISCUSSION
Using PCR amplification of DNA copies of RNA, followed by sequencing of the cloned PCR products, expression of the LPQ-YIDD regions of the pol genes of the multiplecopy endogenous retroviral provirus, HERV-K, was detected in fresh blood cells of normal donors and patients with polycythemia vera, CML or AML. Although the sequence that was determined was short, the sequences obtained from different nonleukemic individuals were still heterogeneous. Because the sequenced region was short, it is possible that these few sequences which were identical in the LPQ-YIDD region were different elsewhere. The relatively large number of different HERV-K pol sequences amplified from normal human leukocyte RNA suggested that selection of HERV-K proviruses for expression in normal blood cells was nearly random. Expression of the HERV-K pol gene was verified by ribonuclease protection. HERV-K transcripts were of low abundance in blood cells or were present in a low proportion of blood cells.
Leukocytes from five leukemia patients expressed a common LPQ-YIDD pol sequence characterized by a noncont -3.7 kb -2.0 kb sensus T at position 41 that generated a stop codon. The common sequence was obtained from leukemia patients over the course of several experiments in which normal and PV donors expressing a variety of sequences were also studied, so the common sequences from leukemia patients cannot be explained by PCR contamination. Southem transfers showed that massive DNA amplification, such as is found in double minutes," did not explain the selective expression of the common sequence, suggesting a transcriptional regulatory mechanism. Three normal donors also expressed the sequence common to the leukemic patients. Any of the sequences that were identical within the LPQ-YIDD region may have been different elsewhere. In particular, the HERV-K provirus expressed in normal donors 4, 6 , and 7 may not have been the same provirus that was expressed in leukemia patients.
Of 5 HERV-K pol sequences expressed in leukocytes from 3 PV patients, 4 showed a characteristic C..A..T or C..A region around nucleotides 39 through 45. The PV sequences were different from one another in other areas of the LPQ-YIDD sequence. Thus, unlike normal donors that appear to randomly express HERV-K proviruses or leukemia patients that predominantly expressed one sequence, PV patients may have expressed a restricted family of related proviruses.
The leukemia patients studied, except CML2, exhibited a variety of white blood cell (WBC) types in peripheral blood and still apparently expressed a common sequence. Therefore, in the blood cell population of the leukemia patients, selective HERV-K expression was probably not restricted to one cell type and may have resulted from a genetic change within a stem cell. The fact that patient AMLl was in remission and also expressed the defective HERV-K pol sequence is in keeping with the persistence of other retroviral-like markers in remission of CMLIR and AML."' The increased frequency of expression of the defective pol sequence in blood cells of leukemic patients (5 of 5). compared with nonleukemics (3 of IO) was statistically significant by Fisher's exact t-test (P = .025, two-sided). Nevertheless, the biologic significance of the selective expression of this sequence in leukemia remains unclear. The fact that the HERV-K pol transcripts from leukemia patients carry a stop codon before the essential YlDD RT domain shows that any
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From polypeptide coded by this gene cannot be the same RT-like DNA polymerase that was isolated from leukemia l e u k o c y t e~l~~~~ and platelets. 18a, 22 Another candidate for the leukocyte RT is the active LI element, Ll-1, recently discovered by Dombroski et a13 and Mathias et a1. 4 Particular HERV-K elements may be selectively expressed in leukemia because the LTR responds to a set of transcription factors that are specific to preleukemic or leukemic cells. These HERV-K proviruses might carry gag or env oncogenes. The HERV-K env gene is related to the env gene of the mouse mammary tumor virus' and MMTV env-related proteins have been reported in human
Alternatively, a proto-oncogene downstream of these HERV-K proviruses may become activated. If HERV-K proviruses can transpose, the transposed LTR might activate a variety of otherwise silent genes. Even if HERV-K proviruses are not consequentially involved in the leukemic process, selective HERV-K expression may allow the identification of transcription factors in preleukemic or leukemic cells. Kongsuwan et alZ4 have shown that retroviral-like intracisternal A-particles inserted into the first exon of the Hox 2.4 gene in the WEHI3 monomyelocytic cell line resulted in both the activation and expression o f Hox 2.4. Their work suggests that endogenous retroviral genes can be leukemogenic. This possibility is being tested by the cloning and characterization of HERV-K elements in normal, PV, and leukemic cells.
